On July 25, 2008, we filed a lawsuit against Teva and Barr for infringement of four Sensipar?
patents.
The lawsuit is based on the Abbreviated New Drug Application (“ANDA”) filed by Teva and Barr which seeks approval to market generic versions of Sensipar?.
(See Note 10, “Contingencies” to the Consolidated Financial Statements. )
These generic versions could compete with Sensipar?
in the future.
Vectibix?
(panitumumab) Vectibix?
is our trademark for our first entirely human monoclonal antibody for the treatment of patients with EGFr expressing mCRC after disease progression on, or following fluoropyrimidine-, oxaliplatin- and irinotecan- containing chemotherapy regimens.
EGFr is a protein that plays an important role in cancer cell signaling and is over-expressed in many human cancers.
Vectibix?
is an entirely human monoclonal antibody that binds with high affinity to EGFrs and interferes with signals that might otherwise stimulate growth and survival of the cancer cell.
The goal of developing entirely human monoclonal antibodies is to offer effective targeted therapies with lessened risk of immune response against these agents.
Vectibix?
received FDA approval in September 2006.
On December 5, 2007, the European Commission granted a conditional marketing authorization for Vectibix?, which was renewed in December 2008, as a monotherapy for the treatment of patients with EGFr expressing mCRC with non-mutated (wild-type) KRAS genes after failure of standard chemotherapy regimens.
We acquired full ownership of Vectibix?
as part of our acquisition of Abgenix, Inc.  (“Abgenix”) in April 2006.
Nplate?
(romiplostim) On August 22, 2008, the FDA approved Nplate?, the first platelet producer for the treatment of thrombocytopenia in splenectomized (spleen removed) and non-splenectomized adults with chronic ITP.
Nplate?, the first FDA approved peptibody protein, works by raising and sustaining platelet counts.
On February 6, 2009, we announced that the European Commission granted marketing authorization for Nplate?
for the treatment of splenectomized adult chronic ITP patients who are refractory to other treatments (e. g.  corticosteroids, immunoglobulins).
In the EU, Nplate?
may also be considered as second line treatment for adult non-splenectomized ITP patients where surgery is contra-indicated.
Product candidates We are currently studying new product candidates, including denosumab, and currently marketed products for new indications, which, if approved, we expect will enter into highly competitive markets.
If successful, these product candidates will face substantial competition from products currently marketed as well as those under development by other biotechnology and pharmaceutical companies.
For example, the bone loss setting, in which denosumab would compete, is currently comprised of three therapeutic classes: bisphosphonates, selective estrogen receptor modulators and anabolic agents.
Competitive intensity will increase in the bone loss setting with the expected approval of new agents.
If denosumab is approved, we would need to significantly expand our sales and marketing capabilities to support its successful launch.
The following table reflects other companies and their currently marketed products that will compete with denosumab, if approved:
## Table 0 ##
Properties, Plants, and Equipment.
Properties, plants, and equipment are recorded at cost.
Depreciation is recorded principally on the straight-line method at rates based on the estimated useful lives of the assets.
The following table details the weighted-average useful lives of structures and machinery and equipment by reporting segment (numbers in years):
## Table 1 ##
Gains or losses from the sale of assets are generally recorded in Other income, net (see policy below for assets classified as held for sale and discontinued operations).
Repairs and maintenance are charged to expense as incurred.
Interest related to the construction of qualifying assets is capitalized as part of the construction costs.
Properties, plants, and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets (asset group) may not be recoverable.
Recoverability of assets is determined by comparing the estimated undiscounted net cash flows of the operations related to the assets (asset group) to their carrying amount.
An impairment loss would be recognized when the carrying amount of the assets (asset group) exceeds the estimated undiscounted net cash flows.
The amount of the impairment loss to be recorded is calculated as the excess of the carrying value of the assets (asset group) over their fair value, with fair value determined using the best information available, which generally is a discounted cash flow (DCF) model.
The determination of what constitutes an asset group, the associated estimated undiscounted net cash flows, and the estimated useful lives of assets also require significant judgments.
Goodwill and Other Intangible Assets.
Goodwill is not amortized; instead, it is reviewed for impairment annually (in the fourth quarter) or more frequently if indicators of impairment exist or if a decision is made to sell or exit a business.
A significant amount of judgment is involved in determining if an indicator of impairment has occurred.
Such indicators may include deterioration in general economic conditions, negative developments in equity and credit markets, adverse changes in the markets in which an entity operates, increases in input costs that have a negative effect on earnings and cash flows, or a trend of negative or declining cash flows over multiple periods, among others.
The fair value that could be realized in an actual transaction may differ from that used to evaluate the impairment of goodwill.
Goodwill is allocated among and evaluated for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment.
Arconic has eight reporting units, of which four are included in the Engineered Products and Solutions segment, three are included in the Transportation and Construction Solutions segment, and the remaining reporting unit is the Global Rolled Products segment.
More than 70% of Arconic’s total goodwill is allocated to two reporting units as follows: Arconic Fastening Systems and Rings (AFSR) ($2,200) and Arconic Power and Propulsion (APP) ($1,647) businesses, both of which are included in the Engineered Products and Solutions segment.
These amounts include an allocation of Corporate’s goodwill.
In November 2014, Arconic acquired Firth Rixson (see Note F), and, as a result recognized $1,801 in goodwill.
This amount was allocated between the AFSR and Arconic Forgings and Extrusions (AFE) reporting units, which is part of the Engineered Products and Solutions segment.
In March and July 2015, Arconic acquired TITAL and RTI, respectively, (see Note F) and recognized $117 and $298, respectively, in goodwill.
The goodwill amount related to TITAL was allocated to the APP reporting unit and the amount related to RTI was allocated to Arconic Titanium and Engineered Products (ATEP), a new Arconic reporting unit that consists solely of the acquired RTI business and is part of the Engineered Products and Solutions segment.
In reviewing goodwill for impairment, an entity has the option to first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not (greater than 50%) that the estimated fair value of a reporting unit is less than its carrying amount.
If an entity elects to perform a qualitative assessment and determines that an impairment is more likely than not, the entity is then required to perform the
Net Interest Analysis The following table presents average balance data and interest income and expense data, as well as the related net interest income:
## Table 2 ##
Net interest income at RJ Bank increased $106.8 million, or 50%, representing more than all of the $55 million increase in our total net interest earnings.
This increase in net interest income at RJ Bank resulted from the significant decline in market rates that occurred early in the fiscal year, leading to lower interest rates being paid on RJ Bank’s retail deposit accounts throughout the year.
RJ Bank benefited as the rates on interest earning assets declined at a much slower pace than rates paid on deposits.
The decline in interest rates had a dramatic impact on net interest in the Private Client Group (“PCG”) segment, which declined $42 million, or 45%.
Interest earned on assets segregated declined $112 million, or 88%, as rates dropped as low as 0.20% for a portion of the year.
Average customer margin balances declined $374 million, or 24%, during 2009, contributing to the decline in interest revenue in the PCG segment.
Net interest earnings in the PCG segment will be negatively affected by our recently introduced multi-bank sweep program.
Begun in mid-September 2009, this program spreads clients’ cash deposits incrementally across a network of unaffiliated banks in amounts less than the single-bank FDIC insurance limits, thereby extending full insurance coverage on client balances of up to $2.5 million, or $5 million if jointly held.
While the program continues to generate competitive interest earnings for clients, it generates fee income for the PCG segment instead of interest earnings.

Tables referenced above, in order (Table 0 first):
<table><tr><td> Amgen Product Candidate</td><td> Therapeutic Area</td><td> Competitor Marketed Product</td><td> Potential Competitor</td></tr><tr><td>Denosumab</td><td>PMO</td><td>FOSAMAX<sup>®</sup></td><td>Merck</td></tr><tr><td>Denosumab</td><td>PMO</td><td>Actonel<sup>®</sup></td><td>Procter & Gamble/Aventis</td></tr><tr><td>Denosumab</td><td>PMO</td><td>Boniva<sup>®</sup>/Bonviva<sup>®</sup></td><td>Roche/GlaxoSmithKline</td></tr><tr><td>Denosumab</td><td>PMO</td><td>Evista<sup>®</sup></td><td>Eli Lilly and Company (“Eli Lilly”)</td></tr><tr><td>Denosumab</td><td>PMO</td><td>Forteo<sup>®</sup>/Forsteo™</td><td>Eli Lilly</td></tr><tr><td>Denosumab</td><td>PMO</td><td>Miacalcin<sup>®</sup></td><td>Novartis</td></tr><tr><td>Denosumab</td><td>PMO</td><td>Aclasta<sup>®</sup>/Reclast<sup>®</sup></td><td>Novartis</td></tr><tr><td>Denosumab</td><td>PMO</td><td>generic ALN</td><td>Teva</td></tr><tr><td>Denosumab</td><td>Oncology</td><td>Zometa<sup>®</sup></td><td>Novartis</td></tr><tr><td>Denosumab</td><td>Oncology</td><td>Aredia<sup>®</sup></td><td>Novartis</td></tr></table>
<table><tr><td>Segment</td><td>Structures</td><td>Machinery and equipment</td></tr><tr><td>Global Rolled Products</td><td>31</td><td>21</td></tr><tr><td>Engineered Products and Solutions</td><td>29</td><td>17</td></tr><tr><td>Transportation and Construction Solutions</td><td>27</td><td>19</td></tr></table>
<table><tr><td></td><td colspan="9">Year Ended</td></tr><tr><td></td><td colspan="3">September 30, 2009</td><td colspan="3">September 30, 2008</td><td colspan="3">September 30, 2007</td></tr><tr><td></td><td></td><td>Operating</td><td>Average</td><td></td><td>Operating</td><td>Average</td><td></td><td>Operating</td><td>Average</td></tr><tr><td></td><td>Average</td><td>Interest</td><td>Yield/</td><td>Average</td><td>Interest</td><td>Yield/</td><td>Average</td><td>Interest</td><td>Yield/</td></tr><tr><td></td><td>Balance</td><td>Inc./Exp.</td><td>Cost</td><td>Balance</td><td>Inc./Exp.</td><td>Cost</td><td>Balance</td><td>Inc./Exp.</td><td>Cost</td></tr><tr><td></td><td colspan="9">($ in 000's)</td></tr><tr><td>Interest-Earning Assets:</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Margin Balances</td><td>$ 1,185,086</td><td>$ 37,617</td><td>3.17%</td><td>$1,559,305</td><td>$ 83,856</td><td>5.38%</td><td>$1,401,931</td><td>$ 108,368</td><td>7.73%</td></tr><tr><td>Assets Segregated Pursuant</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>to Regulations and Other</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Segregated Assets</td><td>4,572,808</td><td>14,786</td><td>0.32%</td><td>4,264,868</td><td>126,556</td><td>2.97%</td><td>3,738,106</td><td>195,356</td><td>5.23%</td></tr><tr><td>Bank Loans, Net</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>of Unearned Income -1</td><td>7,497,674</td><td>320,167</td><td>4.27%</td><td>6,144,131</td><td>346,560</td><td>5.64%</td><td>3,180,331</td><td>204,959</td><td>6.44%</td></tr><tr><td>Available for Sale Securities</td><td>516,977</td><td>24,373</td><td>4.71%</td><td>605,914</td><td>31,700</td><td>5.23%</td><td>428,622</td><td>23,894</td><td>5.57%</td></tr><tr><td>Trading Instruments</td><td></td><td>13,112</td><td></td><td></td><td>31,865</td><td></td><td></td><td>46,182</td><td></td></tr><tr><td>Stock Borrow</td><td></td><td>10,269</td><td></td><td></td><td>36,843</td><td></td><td></td><td>68,685</td><td></td></tr><tr><td>Interest Earnings of Variable</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Interest Entities</td><td></td><td>71</td><td></td><td></td><td>657</td><td></td><td></td><td>955</td><td></td></tr><tr><td>Other</td><td></td><td>23,189</td><td></td><td></td><td>66,026</td><td></td><td></td><td>78,593</td><td></td></tr><tr><td>Total Interest Income</td><td></td><td>443,584</td><td></td><td></td><td>724,063</td><td></td><td></td><td>726,992</td><td></td></tr><tr><td>Interest-Bearing Liabilities:</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Brokerage Client Liabilities</td><td>$ 5,788,338</td><td>10,958</td><td>0.19%</td><td>$5,412,303</td><td>137,511</td><td>2.54%</td><td>$4,619,292</td><td>204,158</td><td>4.42%</td></tr><tr><td>Retail Bank Accounts -1</td><td>8,331,432</td><td>24,023</td><td>0.29%</td><td>7,137,843</td><td>185,032</td><td>2.59%</td><td>4,130,433</td><td>190,762</td><td>4.62%</td></tr><tr><td>Stock Loan</td><td></td><td>3,838</td><td></td><td></td><td>26,552</td><td></td><td></td><td>59,276</td><td></td></tr><tr><td>Borrowed Funds</td><td></td><td>10,845</td><td></td><td></td><td>15,685</td><td></td><td></td><td>13,835</td><td></td></tr><tr><td>Interest Expense of Variable</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Interest Entities</td><td></td><td>4,853</td><td></td><td></td><td>5,604</td><td></td><td></td><td>6,972</td><td></td></tr><tr><td>Other</td><td></td><td>2,436</td><td></td><td></td><td>21,845</td><td></td><td></td><td>24,661</td><td></td></tr><tr><td>Total Interest Expense</td><td></td><td>56,953</td><td></td><td></td><td>392,229</td><td></td><td></td><td>499,664</td><td></td></tr><tr><td>Net Interest Income</td><td></td><td>$ 386,631</td><td></td><td></td><td>$ 331,834</td><td></td><td></td><td>$ 227,328</td><td></td></tr></table>

Question: What was the average value of theSegregated Assets for Balance in the years where Margin Balances is positive?
Answer: 4.19193e+06
Reasoning program: add(4572808,4264868), add(#0,3738106), divide(#1,const_3)